Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Harmony Biosciences Hldgs is well-positioned for future success with its innovative therapies for rare neurological disorders and its strong product WAKIX (pitolisant) already showing promising results. The company's extended half-life compared to competitors, strong safety profile, and potential for a differentiated label in narcolepsy highlight its strong potential. With preliminary 2Q26 revenues exceeding expectations and continued future catalysts, including a potential blockbuster status and a strong IP portfolio, Harmony Biosciences Hldgs presents a buying opportunity for investors. However, potential risks include competition and clinical trial outcomes.

Bears say

Harmony Biosciences Hldgs is currently trading higher, likely in response to the positive Phase 1 data on its drug candidate BP-205, which has potential as a potent OX2R molecule for multiple CNS indications. However, there are some concerns regarding the growth outlook for its main product Wakix, as well as potential competition from generic versions. Additionally, the company's orphan drug pipeline adds potential growth drivers, but there is still uncertainty around their success.

HRMY has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.